Last $9.50 USD
Change Today 0.00 / 0.00%
Volume 51.6K
ADMA On Other Exchanges
Symbol
Exchange
OTC BB
As of 5:20 PM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

adma biologics inc (ADMA) Snapshot

Open
$9.25
Previous Close
$9.50
Day High
$9.50
Day Low
$9.25
52 Week High
08/4/14 - $10.75
52 Week Low
12/26/13 - $6.52
Market Cap
88.3M
Average Volume 10 Days
4.5K
EPS TTM
$-2.08
Shares Outstanding
9.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADMA BIOLOGICS INC (ADMA)

Related News

No related news articles were found.

adma biologics inc (ADMA) Related Businessweek News

No Related Businessweek News Found

adma biologics inc (ADMA) Details

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate, RI-002, which is in Phase III clinical trial, is intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

42 Employees
Last Reported Date: 03/28/14
Founded in 2004

adma biologics inc (ADMA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $484.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $343.9K
Chief Scientific & Medical Officer and Execut...
Total Annual Compensation: $320.5K
Compensation as of Fiscal Year 2013.

adma biologics inc (ADMA) Key Developments

ADMA Biologics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

ADMA Biologics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net loss of $3,961,245 or $0.43 per basic and diluted share on total Revenue was $1,500,319 against net loss of $4,895,444 or $0.83 per basic and diluted share on total Revenue was $743,270 a year ago. Loss from operations was $3,587,320 compared to $4,843,127 a year ago. The narrowed net loss was primarily attributed to lower research and development expenses of approximately $1,700,000 as manufacturing activities for RI-002 were complete during the first quarter of 2014 and one-third of the patients in the Phase III study completed their scheduled infusions during the second quarter of 2014. This was partially offset by increases in costs of product revenue and plasma center expenses attributed to increased sales of normal source plasma, donor collections and associated costs, increased plasma center operating costs as a result of advertising and promotion expenses, increased headcount and facility capital expenditures. For the six months, the company reported net loss of $9,865,117 or $1.06 per basic and diluted share on total Revenue was $3,060,878 against net loss of $8,137,091 or $1.39 per basic and diluted share on total Revenue was $1,536,205 a year ago. Loss from operations was $9,271,306 compared to $7,993,216 a year ago.

ADMA Biologics, Inc. Announces Formation of its Scientific Advisory Board

ADMA Biologics, Inc. announced the formation of its Scientific Advisory Board (SAB) with the following appointments: R. Michael Blaese, M.D., Roy F. Chemaly, M.D., M.P.H., John DeVincenzo, M.D., Richard O'Reilly, M.D., Jordan S. Orange, M.D., Ph.D., and E. Richard Stiehm, M.D. R. Michael Blaese, M.D., is the medical director of the Immune Deficiency Foundation (IDF), Towson, Maryland. Prior to going to work for the IDF, Dr. Blaese spent more than 30 years at the National Institutes of Health (NIH) researching and developing treatments for immune deficiencies. Roy F. Chemaly, M.D., M.P.H., is a professor in the department of infectious diseases, infection control and employee health, division of internal medicine at The University of Texas, MD Anderson Cancer Center. Dr. Chemaly is board certified, specializing in infectious diseases and has published extensively on infections in immunocompromised hosts such as stem cell transplant patients. He is also the director of Infection Control and Antimicrobial Stewardship Programs. John DeVincenzo, M.D. is a practicing pediatric infectious disease specialist, Professor of Pediatrics and Professor of Microbiology, Immunology, and Biochemistry at the University of Tennessee School of Medicine. His research focuses on understanding the pathogenesis of Respiratory Syncytial Virus (RSV) directly in children and using this understanding to develop therapeutic and prevention strategies against this virus. Richard O'Reilly, M.D. is the chair of the department of pediatrics at Memorial Sloan Kettering Cancer Center. Dr. O'Reilly oversees all aspects of the clinical, medical education, and research endeavors. Jordan S. Orange, M.D., Ph.D. is the chief of immunology, allergy, and rheumatology, professor and section head for immunology, allergy and rheumatology in the department of pediatrics at Baylor College of Medicine, and the director of the Center for Human Immunobiology at Texas Children's Hospital. E. Richard Stiehm, M.D. is a distinguished research professor of pediatrics emeritus at the University of California, Los Angeles.

ADMA Biologics, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 12:00 PM

ADMA Biologics, Inc. Presents at JMP Securities Healthcare Conference, Jun-24-2014 12:00 PM. Venue: The Westin New York Grand Central, 212 East 42nd Street, New York, NY 10017, United States. Speakers: Adam S. Grossmann, Founder, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMA:US $9.50 USD 0.00

ADMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADMA.
View Industry Companies
 

Industry Analysis

ADMA

Industry Average

Valuation ADMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 19.2x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADMA BIOLOGICS INC, please visit www.admabiologics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.